HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells

Cancer Biology and Therapy

Volumn 13, Issue 10, 2012, Pages 946-955

  Pineda, Danielle M ^a   Rittenhouse, David W ^a   Valley, Christopher C ^b   Cozzitorto, Joseph A ^a   Burkhart, Richard A ^a   Leiby, Benjamin ^a   Winter, Jordan M ^a   Weber, Matthew C ^a   Londin, Eric R ^a   Rigoutsos, Isidore ^a   Yeo, Charles J ^a   Gorospe, Myriam ^c   Witkiewicz, Agnieska K ^a   Sachs, Jonathan N ^b   Brody, Jonathan R ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b University of Minnesota   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Apoptosis; DR5; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Post transcriptional regulation; TRAIL; TRAIL resistance; TRAILR2

Indexed keywords

CASPASE 8; DEATH RECEPTOR 5; HUR PROTEIN; MESSENGER RNA;

5' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS ADENOCARCINOMA; PANCREAS DUCTAL ADENOCARCINOMA; POSTTRANSCRIPTION REGULATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN SYNTHESIS INHIBITION; TRANSCRIPTION REGULATION; TRANSLATION INITIATION;

5' UNTRANSLATED REGIONS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTOPLASM; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; PANCREATIC NEOPLASMS; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER;

EID: 84864539012     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20952     Document Type: Article

References (32)

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY) 2008; 321:1801-6.
2. López de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, et al. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 2003; 22:7146-54; PMID:14562043; http://dx.doi.org/10.1038/sj.onc. 1206862.
3. López de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2:11-3; PMID:17132932; http://dx.doi.org/10. 4161/rna.2.1.1552.
4. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Current opinion in cell biology.
5. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62; PMID:10411544; http://dx.doi.org/10.1172/JCI6926.
6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63; PMID:9930862; http://dx.doi.org/10.1038/5517.
7. Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 2010; 9:2582-92; PMID:20660600; http://dx.doi.org/10.1158/1535- 7163.MCT-10-0370.
8. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201:331-40; PMID:15389537; http://dx.doi.org/10.1002/jcp.20099.
9. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001; 20:399-403; PMID:11313970; http://dx.doi.org/10.1038/ sj.onc.1204103.
10. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (New York, NY) 1997; 277:815-8. (Pubitemid 27366732)
11. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17:2215-23; PMID:9545235; http://dx.doi.org/10.1093/emboj/17.8.2215.
12. Mahalingam D, Oldenhuis CN, Szegezdi E, et al. Targeting Trail Towards the Clinic. Current drug targets.
13. Abdelmohsen K, Lal A, Kim HH, Gorospe M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell cycle (Georgetown, Tex) 2007; 6:1288-92. (Pubitemid 47327958)
14. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65:3168-81; PMID:18581050; http://dx.doi.org/10.1007/s00018-008- 8252-6.
15. Meng Z, King PH, Nabors LB, Jackson NL, Chen CY, Emanuel PD, et al. The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res 2005; 33:2962-79; PMID:15914670; http://dx.doi.org/10.1093/nar/gki603.
16. Kullmann M, Göpfert U, Siewe B, Hengst L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5' UTR. Genes Dev 2002; 16:3087-99; PMID:12464637; http://dx.doi.org/10.1101/gad.248902.
17. Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley interdisciplinary reviews 1:214-29.
18. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13; PMID:9196156.
19. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Upregulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69:4567-72; PMID:19487279; http://dx.doi.org/10.1158/0008-5472.CAN-09-0371.
20. Richards NG, Rittenhouse DW, Freydin B, et al. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Annals of surgery 2010; 252:499-505.
21. Wang PY, Rao JN, Zou T, Liu L, Xiao L, Yu TX, et al. Post-transcriptional regulation of MEK-1 by polyamines through the RNA-binding protein HuR modulating intestinal epithelial apoptosis. Biochem J 2010; 426:293-306; PMID:20001965; http://dx.doi.org/10.1042/BJ20091459.
22. Durie D, Lewis SM, Liwak U, Kisilewicz M, Gorospe M, Holcik M. RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation. Oncogene 2011; 30:1460-9; PMID:21102524; http://dx.doi.org/10.1038/ onc.2010.527.
23. Mazroui R, Di Marco S, Clair E, von Roretz C, Tenenbaum SA, Keene JD, et al. Caspase-mediated cleavage of HuR in the cytoplasm contributes to pp32/PHAP-I regulation of apoptosis. J Cell Biol 2008; 180:113-27; PMID:18180367; http://dx.doi.org/10.1083/jcb.200709030.
24. Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S, et al. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer 2007; 7:108; PMID:17592646; http://dx.doi.org/10.1186/1471-2407-7-108.
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25:1754-60; PMID:19451168; http://dx.doi.org/10.1093/bioinformatics/btp324.
26. Brody JR, Gonye GE. HuR's Role in Gemcitabine Efficacy: An exception or opportunity? WIREs RNA 2010.
27. Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, et al. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 2000; 20:760-9; PMID:10629032; http://dx.doi.org/10.1128/MCB.20.3.760-9.2000.
28. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region. Mol Cancer Ther 2008; 7:1091-100; PMID:18483298; http://dx.doi.org/10. 1158/1535-7163.MCT-07-2368.
29. Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, et al. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 2008; 27:6151-63; PMID:18641687; http://dx.doi.org/10.1038/ onc.2008.215.
30. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273:6417-23; PMID:9497373; http://dx.doi.org/10.1074/jbc.273.11.6417.
31. von Roretz C, Gallouzi IE. Protein kinase RNA/FADD/caspase-8 pathway mediates the proapoptotic activity of the RNA-binding protein human antigen R (HuR). J Biol Chem 2010; 285:16806-13; PMID:20353946; http://dx.doi.org/10.1074/ jbc.M109.087320.
32. von Roretz C, Macri AM, Gallouzi IE. Transportin 2 regulates apoptosis through the RNA-binding protein HuR. J Biol Chem 2011; 286:25983-91; PMID:21646354; http://dx.doi.org/10.1074/jbc.M110.216184.